

**TRANSMITTAL LETTER TO THE UNITED STATES
DESIGNATED/ELECTED OFFICE (DO/EO/US)
CONCERNING A FILING UNDER 35 U.S.C. 371**

Attorney's Docket Number

040750-5002-US

09/762258

U.S. Application No.

Not Yet Assigned

International Application. No.
PCT/US99/17595

International Filing Date
4 August 1999

Priority Date Claimed
4 August 1998

Title of Invention: IDENTIFICATION AND FUNCTIONAL CHARACTERIZATION OF A NOVEL RIBOSOMAL S6 PROTEIN KINASE

Applicant For DO/EO/US: LUDWIG INSTITUTE FOR CANCER RESEARCH

Applicant timely submits this patent application, the due date for which is extended until Monday, February 5, 2001 under the Next Business Day Rule (MPEP § 710.05). Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.
3. ☐ This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).
4. ☒ A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
5. ☒ A copy of the International Application as filed (35 U.S.C. 371(c)(2))
 - a. ☐ is transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☐ has been transmitted by the International Bureau.
 - c. ☒ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☐ A translation of the International Application into English (35 U.S.C. 371(c)(2)).
7. ☒ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)).
 - a. ☐ are transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☐ have been transmitted by the International Bureau.
 - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
 - d. ☒ have not been made and will not be made.
8. ☐ A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
9. ☐ An oath or declaration of the inventors (35 U.S.C. 371(c)(4)).
10. ☐ A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

Items 11. to 14. below concern other document(s) or information included:

11. ☐ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
12. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
13. ☐ A FIRST preliminary amendment.
14. ☒ Other items or information:
 - a. ☒ WIPO Publication - (98 pages)
 - b. ☒ PCT/IB/304
 - c. ☐ PCT/IB/308
 - d. ☒ PCT/IB/332
 - e. ☒ Statement Accompanying Sequence Listing
 - f. ☒ Sequence Listing (paper copy and diskette)
 - g. ☐ Request to transfer CRF of sequence listing
 - h. ☒ PCT/ISA/210
 - i. ☒ PCT/ISA/220
 - j. ☐ PCT/IPEA/408
 - k. ☒ PCT/IPEA/409

U.S. APPLICATION NO. **09/762258** INTERNATIONAL APPLICATION NO. PCT/US99/17595 ATTORNEY DOCKET NUMBER 040750-5002-US

15. [X] The following fees are submitted:

Basic National Fee (37 CFR 1.492(a)(1)-(5)):

Search Report has been prepared by the EPO or JPO	\$860.00
International preliminary examination fee paid to USPTO (37 CFR 1.482)	\$690.00
No international preliminary examination fee paid to USPTO (37 CFR 1.482) but international search fee paid to USPTO (37 CFR 1.445(a)(2))	\$710.00
Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO	\$1,000.00
International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(2)-(4)	\$100.00
ENTER APPROPRIATE BASIC FEE AMOUNT =	\$860.00

Surcharge of \$130.00 for furnishing the oath or declaration later than [] 20 [] 30 months from the earliest claimed priority date (37 CFR 1.492(e)).

Claims	Number Filed	Number Extra	Rate	
Total Claims	41 - 20 =	21	X \$ 18.00	\$ 378.00
Independent Claims	17 - 3 =	14	X \$ 80.00	\$1,120.00
Multiple dependent claim(s) (if applicable)			+ \$270.00	\$ 270.00
TOTAL OF ABOVE CALCULATIONS =				\$1,768.00
SUBTOTAL =				\$2,628.00

Processing fee of \$130.00 for furnishing the English translation, later than [] 20 [] 30 months from the earliest claimed priority date (37 CFR 1.492(f)).

Reduction by 1/2 for filing by small entity. All entities associated with this application presently fully meet the requirements of 36 CFR §1.9(d).


TOTAL NATIONAL FEE = \$1,314.00

Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property

TOTAL FEES ENCLOSED = \$1,314.00

Amount to be refunded	\$
charged	\$

- a. [X] A check in the amount of **\$1,314.00** to cover the above fees is enclosed.
- b. [] Please charge my Deposit Account No. 50-0310 in the amount of \$.00 to cover the above fees. A duplicate copy of this sheet is enclosed.
- c. [X] **Except** for issue fees payable under 37 C.F.R. §1.18, the Commissioner is hereby authorized by this paper to charge any additional fees during the entire pendency of this application including fees due under 37 CFR §1.16 and §1.17 which may be required, or credit any overpayment to Deposit Account No. 50-0310.



Thomas F. Poché
Reg. No. 45,017

Customer No. 009629
SEND ALL CORRESPONDENCE TO:
Morgan, Lewis & Bockius LLP
1800 M Street, N.W.
Washington, D.C. 20036
(202) 467-7000

Submitted: February 5, 2001

09/762258

JC05 Rec'd PCT/PTO 05 FEB 2001
PATENT

Attorney Docket No. 40750-5002-US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Ivan GOUT <i>et al.</i>)	
)	
Application No.: Unassigned)	Group Art Unit: Unassigned
(based on PCT/US99/17595))	
)	
Filed: February 5, 2001)	Examiner: Unassigned
)	
For: IDENTIFICATION AND FUNCTIONAL)	
CHARACTERIZATION OF A NOVEL)	
RIBOSOMAL S6 PROTEIN KINASE)	

Commissioner for Patents
Washington, D.C. 20231
BOX SEQUENCE

STATEMENT ACCOMPANYING SEQUENCE LISTING


Dear Sir:

The undersigned hereby states upon information and belief that the Sequence Listing submitted concurrently herewith does not include matter which goes beyond the content of the application as filed and that the information recorded on the diskette submitted concurrently herewith is identical to the written Sequence Listing submitted herewith.

Respectfully submitted,

Dated: February 5, 2001

MORGAN, LEWIS & BOCKIUS LLP

By: 

Thomas F. Poché
Registration No. 45,017

MORGAN, LEWIS & BOCKIUS LLP
1800 M Street, N.W.
Washington, D.C. 20036
Tel: 202-467-7000
Fax: 202-467-7176